** Shares of VYNE Therapeutics VYNE.O plummet 72% to an all-time low of 40 cents
** Stock set for its worst day in over 7 years, if losses hold
** Co says its skin disease drug, Repibresib gel, for vitiligo failed to meet its mid-stage trial goals, of improving facial vitiligo by at least 50% or 75%
** VYNE will halt the trial's ongoing extension phase and seek an external partner to continue developing Repibresib
** Repibresib gel caused more mild skin side effects and application site pain than placebo, co says
** Co had about $39.6 million in cash as of June 30
** Including session's move, stock down 88% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。